Stock TMED EGF THERAMED HEALTH CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials EGF Theramed Health Corp.

Equities

TMED

CA2684692023

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 09:56:38 2024-05-16 am EDT 		5-day change 1st Jan Change
0.145 CAD +3.57% Intraday chart for EGF Theramed Health Corp. +3.57% -23.68%
Feb. 26 EGF Theramed Health Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 EGF Theramed Health Corp. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Valuation

Fiscal Period: June 2021 2022 2023
Capitalization 1 5.134 0.6474 5.246
Enterprise Value (EV) 1 5.556 1.852 6.574
P/E ratio -2.76 x -0.48 x -8.02 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -
EV / FCF - -2,976,622 x -29,644,157 x
FCF Yield - -0% -0%
Price to Book 56.1 x -0.63 x -4.59 x
Nbr of stocks (in thousands) 2,054 2,158 10,491
Reference price 2 2.500 0.3000 0.5000
Announcement Date 11/1/21 10/28/22 10/30/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2021 2022 2023
Net sales - - -
EBITDA - - -
EBIT 1 -0.8661 -0.9713 -0.3488
Operating Margin - - -
Earnings before Tax (EBT) 1 -0.7443 -1.364 -0.6435
Net income 1 -0.9735 -1.35 -0.623
Net margin - - -
EPS 2 -0.9069 -0.6266 -0.0624
Free Cash Flow - -0.6222 -0.2218
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 11/1/21 10/28/22 10/30/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2021 2022 2023
Net Debt 1 0.42 1.2 1.33
Net Cash position 1 - - -
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -0.62 -0.22
ROE (net income / shareholders' equity) - 76.9% 26.7%
ROA (Net income/ Total Assets) - -88.3% -117%
Assets 1 - 1.53 0.5321
Book Value Per Share 2 0.0400 -0.4700 -0.1100
Cash Flow per Share 2 0.3400 0.0100 0
Capex - - -
Capex / Sales - - -
Announcement Date 11/1/21 10/28/22 10/30/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EGF THERAMED HEALTH CORP. Stock EGF Theramed Health Corp.
-23.68% 1.17M
MODERNA, INC. Stock Moderna, Inc.
+33.63% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TMED Stock
  4. Financials EGF Theramed Health Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW